冷逸. 肺炎支原体肺炎患儿肺炎支原体免疫球蛋白M抗体阳性显现时间的临床意义[J]. 实用临床医药杂志, 2019, 23(19): 90-92. DOI: 10.7619/jcmp.201919024
引用本文: 冷逸. 肺炎支原体肺炎患儿肺炎支原体免疫球蛋白M抗体阳性显现时间的临床意义[J]. 实用临床医药杂志, 2019, 23(19): 90-92. DOI: 10.7619/jcmp.201919024
LENG Yi. Clinical significance of positive appearance time of mycoplasma pneumoniae immunoglobulin M antibody in children with mycoplasmal pneumonia[J]. Journal of Clinical Medicine in Practice, 2019, 23(19): 90-92. DOI: 10.7619/jcmp.201919024
Citation: LENG Yi. Clinical significance of positive appearance time of mycoplasma pneumoniae immunoglobulin M antibody in children with mycoplasmal pneumonia[J]. Journal of Clinical Medicine in Practice, 2019, 23(19): 90-92. DOI: 10.7619/jcmp.201919024

肺炎支原体肺炎患儿肺炎支原体免疫球蛋白M抗体阳性显现时间的临床意义

Clinical significance of positive appearance time of mycoplasma pneumoniae immunoglobulin M antibody in children with mycoplasmal pneumonia

  • 摘要:
      目的  探讨肺炎支原体肺炎患儿血清抗肺炎支原体免疫球蛋白M抗体(MP-IgM)显现时间的临床意义,分析MP-IgM阳性显现时间不同患儿的临床特点。
      方法  回顾性分析200例肺炎支原体肺炎患儿的临床资料。
      结果  200例肺炎支原体肺炎患儿中,病程7~10 d检出阳性124例,病程11~14 d检出阳性69例,病程15 d及以上(阳性时间较晚)检出阳性7例。
      结论  MP-IgM阳性检出时间较晚的肺炎支原体肺炎患儿临床症状较为严重,治疗较为困难,需加强综合治疗,且不宜因为早期不显现支原体抗体而过早停止对肺炎支原体感染的干预。

     

    Abstract:
      Objective  To investigate the clinical significance of the appearance time of serum anti-mycoplasma pneumonia immunoglobulin M (MP-IgM) antibody in children with mycoplasmal pneumonia, and to analyze the clinical characteristics of children with positive MP-IgM at different time.
      Methods  The clinical materials of 200 children with mycoplasmal pneumonia were retrospectively analyzed.
      Results  Among 200 children with mycoplasmal pneumonia, 124 cases were detected as positive MP-IgM within 7 to 10 days, 69 cases were detected as positive MP-IgM within 11 to 14 days, and 7 cases were detected as positive MP-IgM within 15 days or longer (the positive time was later).
      Conclusion  For children with mycoplasmal pneumonia, the cases with late occurrence time of positive MP-IgM are more serious in manifestations and difficult in treatment, and they should be treated with strengthened therapy, and intervention for mycoplasma pneumoniae infection should not be stopped untimely because there is no mycoplasma antibody in the early stage.

     

/

返回文章
返回